Skip to main content

Advertisement

SpringerLink
Log in

Is alendronate therapy cost-effective for postmenopausal osteopenia?

  • Practice Point
  • Published:

From Nature Clinical Practice Endocrinology & Metabolism

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lewiecki EM (2005) Review of guidelines for bone mineral density testing and treatment of osteoporosis. Curr Osteoporos Rep 3: 75–83

    Article  Google Scholar 

  2. Feldstein A et al. (2003) Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 163: 2165–2172

    Article  Google Scholar 

  3. World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. World Health Organ Tech Rep Ser 843: 1–129

  4. Miller PD et al. (2004) An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med 164: 1113–1120

    Article  Google Scholar 

  5. Wainwright SA et al. (2005) Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 90: 2787–2793

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Clinical Assistant Professor of Medicine at the University of New Mexico School of Medicine, and the Osteoporosis Director at New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA

    E Michael Lewiecki

Authors
  1. E Michael Lewiecki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E Michael Lewiecki.

Ethics declarations

Competing interests

The author receives grant or research support from Merck, Eli Lilly, Novartis, Aventis, Amgen, Pfizer, Wyeth-Ayerst, Roche, and Procter & Gamble, and is a consultant, advisor, or speaker for Merck, Eli Lilly, Novartis, Procter & Gamble, Aventis, Roche, Wyeth-Ayerst, and Servier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lewiecki, E. Is alendronate therapy cost-effective for postmenopausal osteopenia?. Nat Rev Endocrinol 1, 74–75 (2005). https://doi.org/10.1038/ncpendmet0052

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0052

  • Springer Nature Limited

Search

Navigation